F/M Investments’s Corvus Pharmaceuticals CRVS Stock Holding History

F/M Investments’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.46M	Buy	+100,029	New	+$1.6M	0.1%	128

Other funds holding CRVS

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

F/M Investments's CRVS Position: Q1 2026 in Review

F/M Investments opened a new position in Corvus Pharmaceuticals (CRVS) in Q1 2026: 100,029 shares worth $1.46M. The stake represents 0.1% of the portfolio and ranks #128 among its holdings.

164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

F/M Investments held 100,029 shares of Corvus Pharmaceuticals worth $1.46M as of Q1 2026.
Corvus Pharmaceuticals was a new F/M Investments position in Q1 2026.
Corvus Pharmaceuticals made up 0.1% of F/M Investments's portfolio in Q1 2026, its #128 holding.
164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on F/M Investments's 13F filing for Q1 2026, filed 11 May 2026.